This product replaces the IVIS® SpectrumCT system (part number 128201).
For ultimate ease and flexibility, the IVIS SpectrumCT 2 in vivo optical imaging system integrates 2D & 3D bioluminescence and fluorescence imaging with low-dose CT combining both molecular functional and anatomical in vivo imaging into single system.
For research use only. Not for use in diagnostic procedures.
The IVIS SpectrumCT 2 in vivo optical imaging system is an integrated platform that combines the full suite of IVIS optical features including; spectral unmixing and 2D and 3D quantitative bioluminescence & fluorescence imaging, with fast, low dose microCT imaging.
Similar to the IVIS Spectrum 2 (part number CLS158738) optical imaging system, the IVIS SpectrumCT 2 incorporates a CCD camera with eXcelon® coating that enables detection of more signal at higher efficiency across a broader spectrum of wavelengths.
The simple user interface along with advanced visualization and analysis tools are driven by our market leading, easy to use Living Image® software. The IVIS SpectrumCT 2 enables longitudinal workflows to characterize disease progression and therapeutic effect throughout the complete experimental time frame with both quantitative CT and optical reconstructions. Fast imaging and the ability to image multiple animals offers the throughput required to scan large cohorts of animals quickly and draw sound conclusions from your experimental data.
High sensitivity
Exclusivity to patented CCD camera with eXcelon coating for high sensitivity imaging
Combined modalities
Integrating optical imaging with microCT for simultaneous functional and anatomical studies in a single system
High throughput
Standard 5 mice configuration or up to 10 mice capacity using optional manifold
Rapid imaging
Fast data acquisition allows quick visualization of images in real-time
Trans-illumination
Imaging below the specimen for sensitive detection and quantification of deep fluorescent sources
Epi-illumination
Imaging above the specimen ideal for high throughput workflow
Spectral unmixing
Remove autofluorescence & easily identify, separate, and quantify multiplexed fluorescent signals
Analysis software
Broadly adopted, easy to use, and intuitive, Living Image visualization and analysis software
Complimentary Living Image™ software licenses are provided with the IVIS systems and upon request.
The camera and coating facilitate detection of more signal at higher efficiency across a broader spectrum of wavelengths throughout the visible and NIR spectrum - giving you:
Camera highlights
Automated optical and high-performance, low-dose microCT integration enabled through:
Broadly adopted imaging software that sets the industry standard for ease of use and flexibility
IVIS spectrum 2 | IVIS spectrumCT 2 | IVIS lumina S5 | IVIS lumina X5 | IVIS lumina III | IVIS lumina LT | IVIS lumina XRMS | |
---|---|---|---|---|---|---|---|
Capacity | Up to 10 mice* | Up to 10 mice* | Up to 10 mice* | Up to 10 mice* | Up to 5 mice** | Up to 5 mice** | Up to 3 mice |
Benchtop format | ✔ | ✔ | ✔ | ✔ | ✔ | ||
2D Bioluminescence / Fluorescence | ✔/✔ | ✔/✔ | ✔/✔ | ✔/✔ | ✔/✔ | ✔/✔ | ✔/✔ |
3D Bioluminescence / Fluorescence | ✔/✔ | ✔/✔ | |||||
Enhanced Fluorescence capabilities | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | |
Integrated standard x-ray | ✔ | ||||||
Integrated high resolution x-ray | ✔ | ||||||
Integrated CT | ✔ | ||||||
Optical FOV (cm) (Nominal) | 4-22.5 | 4-22.5 | 10-22.5 | 10-22.5 | 5-12(2.6**) | 5-12(2.6**) | 5-12 |
Wavelength range (nm) | 415-850 | 415-850 | 410-865 | 410-865 | 410-865 | 415-875 | 410-865 |
For additional comparison information please refer to the IVIS Comparison flyer under the ‘Resources’ tab *Using optional manifold kit **Using expansion lens |
Dimensions | 65.0 cm (W) x 206.0 cm (H) |
---|
Brand |
IVIS
|
---|---|
Imaging Modality |
2D and 3D Bioluminescence
2D and 3D Fluorescence
microCT
|
Unit Size |
1 Unit
|
Are you looking for resources, click on the resource type to explore further.
Surfactant Protein B (SP-B) deficiency is an uncommon, autosomal recessive lung disorder in term infants. This inability to...
The next breakthrough therapy could begin here. Our comprehensive drug discovery solutions cover every stage, from target...
A large percentage of Type 2 diabetes mortality is related to cardiovascular complications. Consequently, there is a critical need...
Aside from the traditional small-molecule chemotherapeutics or targeted therapy agents that have been widely used in the clinic...
The high heterogeneity, lack of tumor-specific targets, and immunosuppressive tumor microenvironment of solid tumors are all...
Annual epidemics of influenza have occurred throughout history causing tens of millions of deaths. Even a run-of-the-mill...
We are here to answer your questions.